Welcome to our dedicated page for Genetic Technologies Ltd. news (Ticker: $GENE), a resource for investors and traders seeking the latest updates and insights on Genetic Technologies Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Genetic Technologies Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Genetic Technologies Ltd.'s position in the market.
Genetic Technologies (GTG) signed a strategic joint sales & marketing agreement with Wellworks for You Inc. to incorporate geneType tests into its employee wellness solutions, potentially generating 40,000 unit sales in year one. The partnership aims to provide geneType Risk Assessment Testing to Wellworks' 750 employer groups and 2 million covered lives, marking a pivotal milestone for both companies.
Genetic Technologies (GENE) released its Appendix 4C & Quarterly Business Update for Q3 FY24, showcasing key highlights such as cash receipts totaling A$1.8m, a significant increase in geneType adoption, launch of a Comprehensive Risk Assessment Test, and successful fund raising initiatives. The Company also reported on a successful DTC digital media sales campaign in the US and the establishment of a GeneType pilot study in US Breast Screen Imaging Centres.